Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
Completed · Phase 2
Conditions studied: Psoriasis Vulgaris
In brief
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
Key facts
- Study ID
- NCT00287547
- Run by
- Bristol-Myers Squibb
- People needed
- 144
- Starts
- 1997-03-01
- Expected to finish
- 1998-01-01
- Last updated by the study team
- 2011-04-25
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis and documentation of a history of stable psoriasis vulgaris of at least 6 months duration.
- vulgaris total body surfae area involvement of at least 10%
- Failure for toxicity and/or inefficacy of at least one standard anti- psoriatic therapy including topical treatment, phototherapy, photochemotherapy, methotrexate, cyclosporin A or etretinate.
You may not qualify if…
- Male and female subjects who are not willing to receive adequate counseling and exercise adequate contraceptive measures with enrolle on study.
- Functional class (V (ACR) RA or amyloidosis)
- Active vasculitis (except for subcutaneous rheumatoid nodules).
- Subjects with a history of asthma, angioedema or anaphylaxis.
- Subjects with evidence of active or latent bacterial or viral invedtions.
- Subjects with a history or malignancy (except basal cell or superficial squamous cell skin carcinoma).
- body weight > 100 kg (or 220 lbs.)
Where it is running
- Local Institution — San Diego, California, United States
- Local Institution — Chicago, Illinois, United States
- Local Institution — Boston, Massachusetts, United States
- Local Institution — Ann Arbor, Michigan, United States
- Local Institution — New Brunswick, New Jersey, United States
- Local Institution — Portland, Oregon, United States
- Local Institution — Philadelphia, Pennsylvania, United States
- Local Institution — Dallas, Texas, United States
- Local Institution — Salt Lake City, Utah, United States
- Local Institution — Burlington, Vermont, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.